SARS-CoV-2 Nucleoprotein (aa 1-419) Recombinant Antigen, 615 by The Life Science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the U.S. and Canada

SARS-CoV-2 Nucleoprotein (aa 1-419) Recombinant Antigen, 615


SARS-CoV-2 Nucleoprotein (aa 1-419) Recombinant Antigen, 615 by The Life Science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the U.S. and Canada product image
SARS-CoV-2 Nucleoprotein (aa 1-419) Recombinant Antigen, 615
Request Pricing

The Life Science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the U.S. and Canada

Receive your quote directly from the manufacturer.



0 Scientists have reviewed this product


Write the First Review

No Reviews

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the virus strain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus closely related to the SARS virus. A SARS-CoV-2 nucleocapsid antigen can be used to support the detection of SARS-CoV-2 (COVID-19, 2019-nCoV).